A CU research team developed a human melanoma cell line that contains a BRAF G469A mutation. The cell line, called MB3572, can be used be used for drug screening, basic science research, and biological assays. Importantly, the research team used this and other BRAF mutation-containing cell lines to demonstrate that BRAF mutations lead to variability in cell proliferation, 3D invasion, and response to MAPK inhibition.
Turner JA, Bemis JGT, Bagby SM, et al. BRAF fusions identified in melanomas have variable treatment responses and phenotypes. Oncogene. 2019;38(8):1296-1308. doi: 10.1038/s41388-018-0514-7.